These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 22982023)

  • 1. Multidrug resistance-associated protein 1 and lung function decline with or without long-term corticosteroids treatment in COPD.
    Budulac SE; Postma DS; Hiemstra PS; Lapperre TS; Kunz LI; Vonk JM; Marike Boezen H; Timens W;
    Eur J Pharmacol; 2012 Dec; 696(1-3):136-42. PubMed ID: 22982023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhaled fluticasone and salmeterol suppress eosinophilic airway inflammation in chronic obstructive pulmonary disease: relations with lung function and bronchodilator reversibility.
    Perng DW; Wu CC; Su KC; Lee YC; Perng RP; Tao CW
    Lung; 2006; 184(4):217-22. PubMed ID: 17006748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial.
    Lapperre TS; Snoeck-Stroband JB; Gosman MM; Jansen DF; van Schadewijk A; Thiadens HA; Vonk JM; Boezen HM; Ten Hacken NH; Sont JK; Rabe KF; Kerstjens HA; Hiemstra PS; Timens W; Postma DS; Sterk PJ;
    Ann Intern Med; 2009 Oct; 151(8):517-27. PubMed ID: 19841453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study.
    Celli BR; Thomas NE; Anderson JA; Ferguson GT; Jenkins CR; Jones PW; Vestbo J; Knobil K; Yates JC; Calverley PM
    Am J Respir Crit Care Med; 2008 Aug; 178(4):332-8. PubMed ID: 18511702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between CRHR1 polymorphism and improved lung function in response to inhaled corticosteroid in patients with COPD.
    Kim WJ; Sheen SS; Kim TH; Huh JW; Lee JH; Kim EK; Lee JH; Lee SM; Lee S; Lim SY; Shin TR; Yoon HI; Oh YM; Lee SD
    Respirology; 2009 Mar; 14(2):260-3. PubMed ID: 19210659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multidrug resistance-associated protein-1 (MRP1) genetic variants, MRP1 protein levels and severity of COPD.
    Budulac SE; Postma DS; Hiemstra PS; Kunz LI; Siedlinski M; Smit HA; Vonk JM; Rutgers B; Timens W; Boezen HM;
    Respir Res; 2010 May; 11(1):60. PubMed ID: 20487524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study.
    Nathan RA; Rooklin A; Schoaf L; Scott C; Ellsworth A; House K; Dorinsky P
    Clin Ther; 2006 Jan; 28(1):73-85. PubMed ID: 16490581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early intervention with inhaled corticosteroids in subjects with rapid decline in lung function and signs of bronchial hyperresponsiveness: results from the DIMCA programme.
    den Otter JJ; van Schayck CP; Folgering HT; van den Boom G; Akkermans RP; van Weel C
    Eur J Gen Pract; 2007; 13(2):89-91. PubMed ID: 17534745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction.
    Lindberg A; Szalai Z; Pullerits T; Radeczky E
    Respirology; 2007 Sep; 12(5):732-9. PubMed ID: 17875063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial.
    Wouters EF; Postma DS; Fokkens B; Hop WC; Prins J; Kuipers AF; Pasma HR; Hensing CA; Creutzberg EC;
    Thorax; 2005 Jun; 60(6):480-7. PubMed ID: 15923248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD patients.
    Dransfield MT; Feldman G; Korenblat P; LaForce CF; Locantore N; Pistolesi M; Watkins ML; Crim C; Martinez FJ
    Respir Med; 2014 Aug; 108(8):1171-9. PubMed ID: 24998880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study.
    Larsson K; Janson C; Lisspers K; Jørgensen L; Stratelis G; Telg G; Ställberg B; Johansson G
    J Intern Med; 2013 Jun; 273(6):584-94. PubMed ID: 23495860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate (500 microg) inhalation twice daily via accuhaler in Chinese patients with COPD.
    Zheng JP; Yang L; Wu YM; Chen P; Wen ZG; Huang WJ; Shi Y; Wang CZ; Huang SG; Sun TY; Wang GF; Xiong SD; Zhong NS
    Chest; 2007 Dec; 132(6):1756-63. PubMed ID: 17951625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relapse in FEV1 Decline After Steroid Withdrawal in COPD.
    Kunz LIZ; Postma DS; Klooster K; Lapperre TS; Vonk JM; Sont JK; Kerstjens HAM; Snoeck-Stroband JB; Hiemstra PS; Sterk PJ;
    Chest; 2015 Aug; 148(2):389-396. PubMed ID: 25836351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of salmeterol/fluticasone via single versus separate inhalers on exacerbations in severe/very severe COPD.
    Hagedorn C; Kässner F; Banik N; Ntampakas P; Fielder K
    Respir Med; 2013 Apr; 107(4):542-9. PubMed ID: 23337300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Airway inflammation in COPD after long-term withdrawal of inhaled corticosteroids.
    Kunz LI; Ten Hacken NH; Lapperre TS; Timens W; Kerstjens HA; van Schadewijk A; Vonk JM; Sont JK; Snoeck-Stroband JB; Postma DS; Sterk PJ; Hiemstra PS;
    Eur Respir J; 2017 Jan; 49(1):. PubMed ID: 28049170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease.
    Vestbo J; Pauwels R; Anderson JA; Jones P; Calverley P;
    Thorax; 2005 Apr; 60(4):301-4. PubMed ID: 15790985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo.
    Soriano JB; Sin DD; Zhang X; Camp PG; Anderson JA; Anthonisen NR; Buist AS; Burge PS; Calverley PM; Connett JE; Petersson S; Postma DS; Szafranski W; Vestbo J
    Chest; 2007 Mar; 131(3):682-689. PubMed ID: 17356080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term use of fluticasone propionate/salmeterol fixed-dose combination and incidence of nonvertebral fractures among patients with COPD in the UK General Practice Research Database.
    Miller DP; Watkins SE; Sampson T; Davis KJ
    Phys Sportsmed; 2010 Dec; 38(4):19-27. PubMed ID: 21150138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.